ERBB2 and breast carcinoma: Considering that treatment with anti-CD9 antibodies decreases metastasis to the lungs, lymph nodes, and thoracic cavity in TNBC [75], CD9 might also be a potential target of brain metastasis treatment in HER2-positive breast cancer.